Orchard Therapeutics Announces Recent Commercial and Regulatory Progress for Late-stage HSC Gene Therapy Programs and Outlines Key 2022 Milestones

Launch Momentum Building for Libmeldy ® in Europe with Health Technology Assessments Progressing Favorably and Treatment Underway for Multiple Commercial Patients
Initiating U.S. BLA Submission for OTL-200 as Early as Year End 2022; Constructive CMC Meeting with FDA Supports Timeline
EU MAA Submission for OTL-103 in Wiskott-Aldrich Syndrome Expected in Mid-2022 Following Productive Regulatory Interactions
Ended 2021 with approximately $220M in Cash and Investments to Support Operations into the First Half of 2023
BOSTON and LONDON, Jan. 10, 2022 (GLOBE NEWSWIRE) — Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today outlined commercial and regulatory updates and key 2022 milestones …

Read the source article at CentralCharts
2022-01-10 14:00:00